Annual Cash & Cash Equivalents
$34.81 M
+$5.38 M+18.30%
31 December 2023
Summary:
Celldex Therapeutics annual cash & cash equivalents is currently $34.81 million, with the most recent change of +$5.38 million (+18.30%) on 31 December 2023. During the last 3 years, it has fallen by -$9.02 million (-20.58%). CLDX annual cash & cash equivalents is now -79.45% below its all-time high of $169.40 million, reached on 31 December 2013.CLDX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$36.40 M
-$6.34 M-14.83%
01 September 2024
Summary:
Celldex Therapeutics quarterly cash and cash equivalents is currently $36.40 million, with the most recent change of -$6.34 million (-14.83%) on 01 September 2024. Over the past year, it has increased by +$15.27 million (+72.23%). CLDX quarterly cash and cash equivalents is now -78.51% below its all-time high of $169.40 million, reached on 31 December 2013.CLDX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.3% | +72.2% |
| 3 y3 years | -20.6% | -49.6% |
| 5 y5 years | +43.2% | +119.5% |
CLDX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -20.6% | +18.3% | -68.4% | +95.9% |
| 5 y | 5 years | -20.6% | +209.9% | -68.4% | +224.1% |
| alltime | all time | -79.5% | +1350.6% | -78.5% | +1416.6% |
Celldex Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $36.40 M(-14.8%) |
| June 2024 | - | $42.74 M(-62.9%) |
| Mar 2024 | - | $115.08 M(+230.5%) |
| Dec 2023 | $34.81 M(+18.3%) | $34.81 M(+64.7%) |
| Sept 2023 | - | $21.13 M(-25.1%) |
| June 2023 | - | $28.22 M(-47.9%) |
| Mar 2023 | - | $54.12 M(+83.9%) |
| Dec 2022 | $29.43 M(-24.8%) | $29.43 M(+58.4%) |
| Sept 2022 | - | $18.58 M(-34.6%) |
| June 2022 | - | $28.40 M(+12.3%) |
| Mar 2022 | - | $25.29 M(-35.4%) |
| Dec 2021 | $39.14 M(-10.7%) | $39.14 M(-45.8%) |
| Sept 2021 | - | $72.18 M(+66.1%) |
| June 2021 | - | $43.45 M(-37.3%) |
| Mar 2021 | - | $69.31 M(+58.1%) |
| Dec 2020 | $43.84 M(+290.3%) | $43.84 M(+141.5%) |
| Sept 2020 | - | $18.15 M(-73.3%) |
| June 2020 | - | $68.03 M(+199.4%) |
| Mar 2020 | - | $22.72 M(+102.3%) |
| Dec 2019 | $11.23 M(-53.8%) | $11.23 M(-32.3%) |
| Sept 2019 | - | $16.59 M(-16.0%) |
| June 2019 | - | $19.74 M(-37.4%) |
| Mar 2019 | - | $31.53 M(+29.7%) |
| Dec 2018 | $24.31 M(-39.7%) | $24.31 M(-25.9%) |
| Sept 2018 | - | $32.82 M(-25.2%) |
| June 2018 | - | $43.89 M(+10.2%) |
| Mar 2018 | - | $39.82 M(-1.2%) |
| Dec 2017 | $40.29 M(-5.1%) | $40.29 M(-26.4%) |
| Sept 2017 | - | $54.73 M(-17.3%) |
| June 2017 | - | $66.16 M(+55.7%) |
| Mar 2017 | - | $42.50 M(+0.1%) |
| Dec 2016 | $42.46 M(-41.1%) | $42.46 M(+33.8%) |
| Sept 2016 | - | $31.74 M(-2.3%) |
| June 2016 | - | $32.48 M(-48.5%) |
| Mar 2016 | - | $63.02 M(-12.6%) |
| Dec 2015 | $72.11 M(+157.3%) | $72.11 M(+8.0%) |
| Sept 2015 | - | $66.79 M(-18.1%) |
| June 2015 | - | $81.58 M(-33.2%) |
| Mar 2015 | - | $122.17 M(+336.0%) |
| Dec 2014 | $28.02 M(-83.5%) | $28.02 M(-13.9%) |
| Sept 2014 | - | $32.52 M(-20.3%) |
| June 2014 | - | $40.80 M(-28.3%) |
| Mar 2014 | - | $56.90 M(-66.4%) |
| Dec 2013 | $169.40 M(+580.4%) | $169.40 M(+1058.2%) |
| Sept 2013 | - | $14.63 M(-43.5%) |
| June 2013 | - | $25.90 M(-65.8%) |
| Mar 2013 | - | $75.63 M(+203.8%) |
| Dec 2012 | $24.90 M(+109.2%) | $24.90 M(+7.4%) |
| Sept 2012 | - | $23.19 M(+24.9%) |
| June 2012 | - | $18.56 M(-18.4%) |
| Mar 2012 | - | $22.75 M(+91.2%) |
| Dec 2011 | $11.90 M(-44.1%) | $11.90 M(-9.1%) |
| Sept 2011 | - | $13.10 M(+20.9%) |
| June 2011 | - | $10.83 M(+6.8%) |
| Mar 2011 | - | $10.14 M(-52.4%) |
| Dec 2010 | $21.29 M(-62.7%) | $21.29 M(+116.6%) |
| Sept 2010 | - | $9.83 M(-35.2%) |
| June 2010 | - | $15.16 M(-64.5%) |
| Mar 2010 | - | $42.67 M(-25.1%) |
| Dec 2009 | $57.00 M(+28.8%) | $57.00 M(+119.4%) |
| Sept 2009 | - | $25.98 M(-17.9%) |
| June 2009 | - | $31.63 M(-19.6%) |
| Mar 2009 | - | $39.36 M(-11.1%) |
| Dec 2008 | $44.26 M(+801.5%) | $44.26 M(+3.7%) |
| Sept 2008 | - | $42.70 M(-18.5%) |
| June 2008 | - | $52.38 M(+358.7%) |
| Mar 2008 | - | $11.42 M(+132.6%) |
| Dec 2007 | $4.91 M(-88.0%) | $4.91 M(-75.9%) |
| Sept 2007 | - | $20.34 M(-21.5%) |
| June 2007 | - | $25.91 M(-20.5%) |
| Mar 2007 | - | $32.57 M(-20.4%) |
| Dec 2006 | $40.91 M | $40.91 M(-12.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2006 | - | $46.68 M(-12.7%) |
| June 2006 | - | $53.47 M(-10.5%) |
| Mar 2006 | - | $59.76 M(+155.2%) |
| Dec 2005 | $23.42 M(-26.2%) | $23.42 M(+5.5%) |
| Sept 2005 | - | $22.20 M(-17.9%) |
| June 2005 | - | $27.03 M(-1.0%) |
| Mar 2005 | - | $27.31 M(-14.0%) |
| Dec 2004 | $31.74 M(+56.7%) | $31.74 M(-9.9%) |
| Sept 2004 | - | $35.23 M(-10.5%) |
| June 2004 | - | $39.37 M(-4.4%) |
| Mar 2004 | - | $41.16 M(+103.3%) |
| Dec 2003 | $20.25 M(-19.2%) | $20.25 M(-13.8%) |
| Sept 2003 | - | $23.50 M(+38.4%) |
| June 2003 | - | $16.98 M(-14.0%) |
| Mar 2003 | - | $19.75 M(-21.2%) |
| Dec 2002 | $25.07 M(-41.2%) | $25.07 M(-4.7%) |
| Sept 2002 | - | $26.31 M(-16.9%) |
| June 2002 | - | $31.67 M(-14.5%) |
| Mar 2002 | - | $37.05 M(-13.2%) |
| Dec 2001 | $42.67 M(-15.0%) | $42.67 M(+22.8%) |
| Sept 2001 | - | $34.74 M(-14.7%) |
| June 2001 | - | $40.71 M(-9.8%) |
| Mar 2001 | - | $45.11 M(-10.1%) |
| Dec 2000 | $50.18 M(+268.4%) | $50.18 M(+3.4%) |
| Sept 2000 | - | $48.51 M(+202.1%) |
| June 2000 | - | $16.06 M(-14.4%) |
| Mar 2000 | - | $18.76 M(+37.8%) |
| Dec 1999 | $13.62 M(+53.0%) | $13.62 M(-13.8%) |
| Sept 1999 | - | $15.80 M(+88.1%) |
| June 1999 | - | $8.40 M(-23.6%) |
| Mar 1999 | - | $11.00 M(+23.6%) |
| Dec 1998 | $8.90 M(+39.1%) | $8.90 M(+23.6%) |
| Sept 1998 | - | $7.20 M(+38.5%) |
| June 1998 | - | $5.20 M(-36.6%) |
| Mar 1998 | - | $8.20 M(+28.1%) |
| Dec 1997 | $6.40 M(-49.2%) | $6.40 M(-24.7%) |
| Sept 1997 | - | $8.50 M(-20.6%) |
| June 1997 | - | $10.70 M(-12.3%) |
| Mar 1997 | - | $12.20 M(-3.2%) |
| Dec 1996 | $12.60 M(+2.4%) | $12.60 M(-12.5%) |
| Sept 1996 | - | $14.40 M(+114.9%) |
| June 1996 | - | $6.70 M(-28.7%) |
| Mar 1996 | - | $9.40 M(-23.6%) |
| Dec 1995 | $12.30 M(+61.8%) | $12.30 M(+98.4%) |
| Sept 1995 | - | $6.20 M(-41.0%) |
| June 1995 | - | $10.50 M(-18.6%) |
| Mar 1995 | - | $12.90 M(+69.7%) |
| Dec 1994 | $7.60 M(-73.1%) | $7.60 M(-59.4%) |
| Sept 1994 | - | $18.70 M(-10.1%) |
| June 1994 | - | $20.80 M(-14.8%) |
| Mar 1994 | - | $24.40 M(-13.8%) |
| Dec 1993 | $28.30 M(+757.6%) | $28.30 M(+133.9%) |
| Sept 1993 | - | $12.10 M(-11.0%) |
| June 1993 | - | $13.60 M(-12.8%) |
| Mar 1993 | - | $15.60 M(-17.9%) |
| Dec 1992 | $3.30 M(-85.1%) | - |
| Oct 1992 | - | $19.00 M(-8.2%) |
| July 1992 | - | $20.70 M(-6.3%) |
| Apr 1992 | - | $22.10 M(-4.3%) |
| Apr 1992 | $22.10 M(+154.0%) | - |
| Jan 1992 | - | $23.10 M(-3.8%) |
| Oct 1991 | - | $24.00 M(-5.9%) |
| July 1991 | - | $25.50 M(+193.1%) |
| Apr 1991 | $8.70 M(-23.0%) | $8.70 M(+7.4%) |
| Jan 1991 | - | $8.10 M(-12.9%) |
| Oct 1990 | - | $9.30 M(-15.5%) |
| July 1990 | - | $11.00 M(-2.7%) |
| Apr 1990 | $11.30 M(+17.7%) | $11.30 M(+56.9%) |
| Jan 1990 | - | $7.20 M(-25.0%) |
| Apr 1989 | $9.60 M(-11.1%) | $9.60 M(-11.1%) |
| Apr 1988 | $10.80 M(-20.0%) | $10.80 M(-20.0%) |
| Apr 1987 | $13.50 M(+462.5%) | $13.50 M(+462.5%) |
| Apr 1986 | $2.40 M | $2.40 M |
FAQ
- What is Celldex Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Celldex Therapeutics?
- What is Celldex Therapeutics annual cash & cash equivalents year-on-year change?
- What is Celldex Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Celldex Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CLDX is $34.81 M
What is the all time high annual cash & cash equivalents for Celldex Therapeutics?
Celldex Therapeutics all-time high annual cash & cash equivalents is $169.40 M
What is Celldex Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CLDX annual cash & cash equivalents has changed by +$5.38 M (+18.30%)
What is Celldex Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CLDX is $36.40 M
What is the all time high quarterly cash and cash equivalents for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly cash and cash equivalents is $169.40 M
What is Celldex Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CLDX quarterly cash and cash equivalents has changed by +$15.27 M (+72.23%)